Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
90.73
+0.99 (1.10%)
At close: Dec 20, 2024, 4:00 PM
91.00
+0.27 (0.30%)
After-hours: Dec 20, 2024, 4:52 PM EST
Axsome Therapeutics Employees
Axsome Therapeutics had 545 employees as of December 31, 2023. The number of employees increased by 162 or 42.30% compared to the previous year.
Employees
545
Change (1Y)
162
Growth (1Y)
42.30%
Revenue / Employee
$621,022
Profits / Employee
-$570,560
Market Cap
4.40B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Integer Holdings | 10,500 |
Alkermes | 2,100 |
Apellis Pharmaceuticals | 706 |
PROCEPT BioRobotics | 626 |
ADMA Biologics | 624 |
TG Therapeutics | 264 |
Krystal Biotech | 229 |
Scholar Rock Holding | 150 |
AXSM News
- 22 days ago - Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data - Seeking Alpha
- 24 days ago - Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says - Benzinga
- 5 weeks ago - Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell - Seeking Alpha
- 6 weeks ago - Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 - GlobeNewsWire
- 7 weeks ago - Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 - GlobeNewsWire
- 2 months ago - Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 - GlobeNewsWire
- 3 months ago - Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine - GlobeNewsWire